°³È¸Àü ¿öÅ©¼¥ - 10¿ù 21ÀÏ - ÀϺ» Ç¥ÁؽÃ(GMT+09:00)
°³È¸Àü ¿öÅ©¼¥ - 10¿ù 21ÀÏ - ÀϺ» Ç¥ÁؽÃ(GMT+09:00)
Á¢¼ö
¸ð´× ¿öÅ©¼¥ : CDMO °ü¸®ÀÇ °³¿ä
Add-on this optional pre-conference workshop to your main conference registration package and gain a comprehensive overview of CDMO Management in an easy-to-follow classroom setting to help you prepare for the main conference program.
Understanding the Japanese CDMO Landscape
- Introduction to Japanese Business Culture
- Historical Overview and Current Trends in the CDMO Industry
- Interactive Discussion
- Participants share their current understanding and experiences with Japanese CDMOs.
- Group activity: Identify key cultural differences that could impact business relationships.
Strategic Partnering with Japanese CDMOs
- Key Players and Capabilities in the Japanese CDMO Market
- CDMO Selection Frameworks
- Case Study, groups and presentations: CDMO Selection
Negotiation and Collaboration
- Collaboration Models
- Case Study, groups and presentations: Negotiation and Collaboration
- Small Group Discussions: Aligning Expectations
Execution, Relationship Maintenance, and Conflict Resolution
- Executing a Seamless Tech Transfer
- Maintaining Relationships and Conflict Resolution
- Interactive Session: Win-Win Thinking in Practice
- Final Q&A and Wrap-Up
- Workshop registration begins at 7:30 am
¿öÅ©¼¥ Á¢¼ö °³½Ã ½Ã°££º¿ÀÀü7£º30 - Morning Break: -10:30-10:50
È޽Ľð££º¿ÀÀü10:30-10:50
- Stefan Sandstrom - CEO, Biosector Ltd., Japan
¿ÀÂùȸ : ¸ÞÀÎ ÄÁÆÛ·±½º£«¹ÝÀϰ£ ¿öÅ©¼¥(2ȸºÐ) ÆÐ½º Ȧ´õ¿ë
¿ÀÈÄ ¿öÅ©¼¥ : ¼¼Æ÷¡¤À¯ÀüÀÚ Á¦Á¶ÀÇ °³¿ä
Add-on this optional pre-conference workshop to your main conference registration package and gain a comprehensive overview of Cell and Gene Therapy Manufacturing in an easy-to-follow classroom setting to help you prepare for the main conference program.
- Workshop registration begins at 12:30 pm
¿öÅ©¼¥ Á¢¼ö °³½Ã ½Ã°££º¿ÀÈÄ12£º30 - Afternoon Break: 3:30-3:50pm
È޽Ľð££º¿ÀÈÄ3:30-3:50
How does Cell and Gene Therapy Manufacturing Differ from other Biological Products?
- The manufacturing diversity of cell and gene products, examples.
- Limitations when controlling adventitious agents
- Complex starting and raw materials
- Batch size, and stability
- Christopher Bravery - Consulting Regulatory Scientist, Consulting on Advanced Biologicals, UK
* ÁÖÃÖÃø »çÁ¤¿¡ µû¶ó »çÀü ¿¹°í¾øÀÌ ÇÁ·Î±×·¥ÀÌ º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù.